Physical and Chemical Study of Atherosclerosis Mechanisms
NCT01700075 on ClinicalTrials.gov · last registry update 2012-10-04
Finished December 2009, after enrolling 97 people. Primary outcome, as filed: full recovery from atherosclerotic diseases. exenatide is approved in the US, but not for cardiovascular disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Nazarbayev University
- Sponsor type
- Other
- Enrollment
- 97
- Started
- 2009-01
- Primary completion
- 2009-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
full recovery from atherosclerotic diseases
Conditions studied
Myocardial Infarction · Coronary Artery Diseases · Diabetes Mellitus, Type 2 · Atherosclerosis of Femoral Artery
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.